Atosiban
Also known as: 1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn-oxytocin, ATSB, RWJ-22164, Tractocile
Source Atosiban at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Atosiban is a synthetic cyclic nonapeptide used intravenously as a tocolytic to delay preterm labor by blocking oxytocin receptors.
Mechanism of Action
Competitive antagonist at oxytocin receptors in uterine smooth muscle, reducing calcium influx and inhibiting uterine contractions
Routes of Administration
Goals & Uses
- Dysmenorrhea treatmentGynecologyLow
- TocolysisObstetricsModerate
- Tocolysis (preterm labor inhibition)ObstetricsHigh
- Endometrial receptivity improvement (IVF)Reproductive MedicineLow
- Reduction of uterine contractionsObstetricsHigh
Contraindications
- Hypersensitivity to atosiban or excipientsAllergicHigh
- Intrauterine infection (chorioamnionitis)InfectiousHigh
- Gestational age < 24 weeks or > 33+6 weeksObstetricHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- Placenta praevia with hemorrhageObstetricHigh
- Severe cardiovascular diseaseCardiovascularHigh
- Severe preeclampsia or eclampsiaObstetricHigh
- Intrauterine fetal death or lethal fetal anomalyFetalHigh
Adverse Effects
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- Injection site reactionsLocalCommon
- Tachycardia (maternal)CardiovascularUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- HypotensionCardiovascularRareLow blood pressure
- FlushingVascularUncommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
Drug Interactions
- OxytocinHigh
- Other tocolytics (e.g., nifedipine)Moderate
- Betamimetics (e.g., ritodrine, terbutaline)Moderate
Population Constraints
- Multiple gestationObstetricRelative
- Hepatic impairment (severe)HepaticRelative
- Renal impairmentOrgan ImpairmentRelative
- Gestational age < 24 weeksObstetricAbsolute
- Gestational age >34 weeksObstetricRelative
- Multiple gestation pregnanciesObstetricRelative
Regulatory Status
- European UnionApprovedApproved: Preterm labor (tocolysis)Marketed as Tractocile.
- United StatesUnapprovedNot submitted for FDA approval.
- United KingdomApprovedApproved: Tocolysis for preterm labor between 24 and 33 weeks gestationApproved and available post-Brexit under MHRA; consistent with prior EU approval
Approved for tocolysis in the European Union and several other countries; not approved by the US FDA.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Atosiban?
Atosiban is a synthetic cyclic nonapeptide used intravenously as a tocolytic to delay preterm labor by blocking oxytocin receptors.
What is Atosiban used for?
Atosiban is educationally associated with: Dysmenorrhea treatment, Tocolysis, Tocolysis (preterm labor inhibition), Endometrial receptivity improvement (IVF), Reduction of uterine contractions. Educational only — not medical advice.
How is Atosiban administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Atosiban?
Reported adverse effects include: Hyperglycemia, Injection site reactions, Tachycardia (maternal), Headache, Hypotension, Flushing, Nausea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Atosiban?
Recorded contraindications: Hypersensitivity to atosiban or excipients, Intrauterine infection (chorioamnionitis), Gestational age < 24 weeks or > 33+6 weeks, Severe hepatic impairment, Placenta praevia with hemorrhage, Severe cardiovascular disease, Severe preeclampsia or eclampsia, Intrauterine fetal death or lethal fetal anomaly. Consult a qualified clinician before use.